Personalized Healthcare in Autoimmune Diseases - Genomic Biomarkers for Pharmaceutical Development - page 55

FIGURE 3.3 Median type I IFN (A and B) GS profiles and (C and D) percent remaining GS in diffuse SSc patients following single or multiple IV
administrations of MEDI-546 in (A and C) whole blood specimens or (B and D) skin specimens from MI-CP180 trial. For each pair of plots, the single
and multiple-dose treatment cohorts have been separated into their respective graph. The x axis represents time from the start of the study in days,
where day 0 is pre dosing. Target modulation for each dose cohort is reported as a percentage from starting values of 100%, so each point post treat-
ment for each cohort indicates the median percentage of remaining gene signature (GS). Only baseline positive GS 0 score SSc patients were plotted. The
minimum and average GS score among the pool of normal healthy controls are shown as the black dashed line and red dashed line respectively (A and
B). Courtesy of Clin Pharm Ther [38] .